Zempem Injection 1g (Meropenem Hydrate)

Adult administration

As Meropenem Hydrate, administer 0.5 to 1 g (potency) daily in 2 to 3 divided doses via intravenous infusion over at least 30 minutes. For suspected infections in pathogenic pneumonia, peritonitis, and patients with neutropenia, administer 1 g (potency) via intravenous infusion every 8 hours. For cystic fibrosis and meningitis, administer 2 g (potency) via intravenous infusion every 8 hours.

Child administration

In the case of bacterial meningitis for children above 3 months of age, administer 40 mg per kg of body weight every 8 hours via intravenous infusion over at least 30 minutes, depending on pathogen susceptibility, patient's condition, and type of infection. Symptoms

This medicine should not be administered to patients who have previously experienced a shock reaction to it. Patients taking sodium valproate should not use this medicine as it may lower the serum concentration of valproate, increasing the risk of seizure recurrence. Patients who have shown allergic reactions to this drug or its components should avoid using it. Patients with severe allergic reactions to other carbapenem antibiotics or beta-lactam antibiotics (e.g., penicillin, cephalosporins) should not be given this medication. Patients with a history of allergic predisposition or those who frequently experience allergy symptoms such as bronchial asthma or rashes should use this medication with caution. Patients with impaired renal function may experience elevated serum concentrations of this drug, leading to central nervous system side effects such as seizures or altered consciousness, so dosage adjustments or increased intervals between administrations may be necessary. Patients with a history of seizures or central nervous system disorders may also experience seizures or altered consciousness when using this medication, so caution is advised. Patients with severe liver dysfunction may experience worsening liver function with this medication, necessitating careful monitoring. Elderly patients may show an increased risk of side effects due to decreased bodily function; therefore, dosage and administration intervals should be adjusted and closely monitored. Patients who have difficulty taking medications orally or those with poor nutritional status may show symptoms of vitamin K deficiency, requiring careful monitoring. Use in infants less than 3 months is not recommended due to the lack of established safety and efficacy. During treatment with this medication, severe allergic reactions such as shock or anaphylaxis may occur very rarely, necessitating close observation of the patient and immediate cessation of administration should symptoms arise. Hypersensitivity reactions such as rashes, hives, fever, and itching may occur; in such cases, administration should be stopped and appropriate treatment is necessary. Blood tests may reveal abnormalities in the blood system such as leukopenia, anemia, thrombocytopenia, so regular monitoring is required, and administration should be halted in the event of abnormal findings. Hepatic dysfunction, hepatitis, and liver failure may occur, thus regular liver function tests should be performed and administration should cease if abnormalities are found. Renal function may deteriorate rapidly, hence regular renal function monitoring is necessary, and administration should stop if abnormalities are identified. If severe diarrhea or abdominal pain occurs, it could indicate severe colitis, such as membranous colitis, warranting immediate cessation of administration and treatment. Symptoms of the central nervous system, such as seizures or altered consciousness, require immediate cessation of administration and appropriate treatment. Signs of respiratory distress, asthma, or pneumonia must be carefully monitored during treatment.

Serious side effects

Shock, anaphylactic reactions, severe allergic reactions, hives, angioedema, severe skin reactions, toxic epidermal necrolysis, drug reaction (DRESS syndrome), erythema multiforme, acute generalized exanthematous pustulosis, severe skin abnormal reactions, fulminant hepatitis, liver dysfunction, jaundice, liver failure, acute renal failure, severe renal impairment, severe colitis, asthma, respiratory distress, interstitial pneumonia, pulmonary edema, PIE syndrome, seizures

Mild side effects

• Oral irregularities
• wheezing
• dizziness
• changes in stool
• tinnitus
• sweating
• warmth
• erythema
• itching
• fever

This medicine should be stored in a tightly sealed container protected from air and moisture. It is recommended to maintain a storage temperature between 1 to 30 degrees Celsius at room temperature. This way, the efficacy of the medicine can be safely preserved.

Appearance

A crystalline powder that is white to pale yellow contained in a colorless transparent vial for injection

Package unit

10 vials